Biodesix, Inc.

Biodesix is a CLIA-certified and CAP-accredited life sciences diagnostics company specializing in AI-driven, blood-based diagnostic tests for lung cancer and related respiratory diseases. Founded in 2005 and publicly traded since 2020, the company combines multi-omic approaches—including genomics, proteomics, and advanced mass spectrometry—with proprietary artificial intelligence algorithms to deliver personalized diagnostic solutions. Flagship offerings include the Nodify Lung Nodule Risk Assessment and IQLung Strategy Tests, which guide clinical decision-making for lung nodule management and non-small cell lung cancer treatment selection. Beyond clinical diagnostics, Biodesix operates a robust biopharma services division providing translational research, biomarker discovery, companion diagnostic development, and clinical trial support to leading biopharmaceutical and research institutions. The company's liquid biopsy technology platform enables non-invasive risk stratification and prognostic assessment, addressing a critical clinical need in early cancer detection and precision oncology.